La vendita allo scoperto per Vivani Medical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Vivani Medical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Vivani Medical (NASDAQ:VANI) Azioni, Report sulle vendite allo scoperto

Vivani Medical

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

General

VANI

L&#39;impianto GLP-1 di Vivani Medical riduce drasticamente l&#39;82% del grasso epatico: risultati preclinici promettenti per l&#39;obesità.

L&#39;impianto di Vivani riduce drasticamente il grasso epatico

Long Ideas

Penny Stocks

Markets

Trading Ideas

CYAN

Le recenti transazioni degli insider su Cyanotech, RENN Fund e Vivani Medical indicano fiducia nel mercato delle penny stock.

Penny stock: gli insider muovono il mercato con acquisti strategici

Vivani Medical Inc

Vivani Medical Inc Warrants (14/03/2024)

Vanilla Network

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 5 years by 2.45% on an annualized basis producing an average annual return of 16.09%. Currently, Marsh &amp; McLennan has a market capitalization of $112.78 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 5 years ago, it would be worth $2,108.08 today based on a price of $229.63 for MMC at the time of writing.
<h3>Marsh &amp; McLennan's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732543245_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

6 analysts have expressed a variety of opinions on NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.93, with a high estimate of $8.00 and a low estimate of $3.90. Observing a downward trend, the current average is 1.82% lower than the prior average price target of $6.04. 
<img src="https://www.benzinga.com/files/images/story/2024/1732543244_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive NIO is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tina Hou</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$3.90</td>
<td>$4.80</td>
</tr>
<tr>
<td>Eugene Hsiao</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.80</td>
<td>$6.60</td>
</tr>
<tr>
<td>Eugene Hsiao</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$6.60</td>
<td>-</td>
</tr>
<tr>
<td>Nick Lai</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$5.30</td>
</tr>
<tr>
<td>Ming Hsun Lee</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.30</td>
<td>$5.00</td>
</tr>
<tr>
<td>Jeff Chung</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$8.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NIO. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NIO compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for NIO's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of NIO's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NIO analyst ratings.</a>
<h2>Discovering NIO: A Closer Look</h2>
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.
<h3>NIO: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining NIO's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.06% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: NIO's net margin is impressive, surpassing industry averages. With a net margin of -27.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): NIO's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -37.5%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): NIO's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.03% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.99, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Unveiling 6 Analyst Insights On NIO

H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect H World Group to report an earnings per share (EPS) of $0.65.
The market awaits H World Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.21 in the last quarter, leading to a 3.07% increase in the share price on the following day.
Here's a look at H World Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.74</td>
<td>0.28</td>
<td>0.36</td>
<td>0.43</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.53</td>
<td>0.34</td>
<td>0.29</td>
<td>0.58</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732543241_0.png" alt="eps graph" />
<h3>Market Performance of H World Group's Stock</h3>
Shares of H World Group were trading at $35.8 as of November 22. Over the last 52-week period, shares are down 2.51%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/HTHT/earnings">To track all earnings releases for H World Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

HTHT

Examining the Future: H World Group's Earnings Outlook

Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) has outperformed the market over the past 5 years by 19.74% on an annualized basis producing an average annual return of 33.37%. Currently, Wingstop has a market capitalization of $9.86 billion. 
Buying $1000 In WING: If an investor had bought $1000 of WING stock 5 years ago, it would be worth $4,220.00 today based on a price of $337.60 for WING at the time of writing.
<h3>Wingstop's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732543239_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WING

Here's How Much $1000 Invested In Wingstop 5 Years Ago Would Be Worth Today

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-26. Here's a quick overview of what investors should know before the release.
Analysts are estimating that HP will report an earnings per share (EPS) of $0.93.
Anticipation surrounds HP's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 2.01% increase in the share price on the subsequent day.
Here's a look at HP's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.86</td>
<td>0.81</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.83</td>
<td>0.82</td>
<td>0.81</td>
<td>0.9</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>17.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732543232_0.png" alt="eps graph" />
<h3>Market Performance of HP's Stock</h3>
Shares of HP were trading at $38.13 as of November 22. Over the last 52-week period, shares are up 33.14%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/HPQ/earnings">To track all earnings releases for HP visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into HP's Upcoming Earnings

In the last three months, 10 analysts have published ratings on Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Guess, presenting an average target of $27.5, a high estimate of $29.00, and a low estimate of $21.00. This current average has decreased by 5.17% from the previous average price target of $29.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732543230_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Guess. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Guess. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Guess compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Guess's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Guess's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GES/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Guess analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Guess Better</h2>
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
<h3>Guess's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Guess's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.24% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Guess's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Guess's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.04%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Guess's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.39%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.86, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 10 Ratings For Guess

Across the recent three months, 5 analysts have shared their insights on Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $6.8, a high estimate of $10.00, and a low estimate of $6.00. This current average represents a 10.53% decrease from the previous average price target of $7.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1732543220_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Vera Bradley. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vera Bradley. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vera Bradley compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Vera Bradley's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vera Bradley's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vera Bradley analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Vera Bradley</h2>
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the most. most of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
<h3>Vera Bradley's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Vera Bradley faced challenges, resulting in a decline of approximately -13.54% in revenue growth as of 31 July, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Vera Bradley's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.15% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.34%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.53%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Vera Bradley adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Vera Bradley Through The Eyes Of 5 Analysts

Psychedelics biotech company Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate., such as ataxia or hyperthermia.
"Completion of these animal PK studies further supports our efforts to develop conveniently delivered, orally-available drugs with the potential to harness neuroplastic properties without inducing hallucinations," stated Joseph Tucker, Ph.D., CEO of Enveric. "The additional data gained in these animal studies enhances our understanding of the preclinical profile of this drug candidate and brings us a step closer to finalizing the data package for the EB-003 Investigational New Drug (IND) application, which we anticipate submitting to the U.S. Food and Drug Administration in the second half of 2025."
Additionally, significant brain penetration was demonstrated in the rat model with a brain/plasma ratio of about 5-6, which is significantly higher than in previous mouse studies. This suggests enhanced efficacy, lower doses and less off-target side effects if these findings are confirmed in clinical trials.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42039385/enveric-biosciences-trims-losses-eyes-key-drug-approval-for-difficult-to-treat-mental-health-disorders">Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
"Mental health disorders like depression and anxiety are on the rise, with approximately one billion people globally expected to experience a neuropsychiatric disorder at some time in their lives,&#8221; Tucker continued. &#8220;Despite the prevalence of these conditions, currently approved treatments fail to provide adequate relief for half of the patients who try them, resulting in widespread challenges to the psychiatric community. The market opportunity for neuroplastogens is estimated to exceed $35 billion by 2030, with the potential to offer low side-effects, strong efficacy, and potential synergies with current drugs, which could help drive demand for new and innovative treatment options."
This update on EB-003 follows the company's announcement of<a href="https://www.benzinga.com/general/biotech/24/11/41714040/enveric-biosciences-expands-mental-health-patent-portfolio-with-5-new-additions"> securing five new U.S. patents</a> for its EVM301 <a href="https://www.benzinga.com/cannabis" target="_blank" rel="noreferrer noopener">portfolio.</a> These latest additions bring Enveric&#8217;s total to nine issued U.S. patents, enhancing the intellectual property surrounding its library of neuroplasticity-focused compounds aimed at mental health conditions.
Price Action
Enveric Biosciences shares closed Friday's market session 0.24% higher at 33 cents per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42146118/how-to-navigate-difficult-psychedelic-journeys-research-insights">How To Navigate Difficult Psychedelic Journeys: Research Insights</a></li>
</ul>
Photo via Shutterstock

Cannabis

Psychedelics

ENVB

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results

In the latest quarter, 26 analysts provided ratings for e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">18</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $177.46, a high estimate of $223.00, and a low estimate of $115.00. This current average represents a 13.79% decrease from the previous average price target of $205.84. 
<img src="https://www.benzinga.com/files/images/story/2024/1732543210_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of e.l.f. Beauty among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$115.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$131.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$139.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$223.00</td>
<td>$223.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to e.l.f. Beauty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of e.l.f. Beauty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for e.l.f. Beauty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of e.l.f. Beauty's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on e.l.f. Beauty analyst ratings.</a>
<h2>Delving into e.l.f. Beauty's Background</h2>
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.
<h3>e.l.f. Beauty's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining e.l.f. Beauty's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.71% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: e.l.f. Beauty's net margin excels beyond industry benchmarks, reaching 6.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): e.l.f. Beauty's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.66%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): e.l.f. Beauty's ROA stands out, surpassing industry averages. With an impressive ROA of 1.56%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 26 Analyst Evaluations For e.l.f. Beauty

Succession Reinforces Long-Term Focus of Company
Brown-Forman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFA#NYSE">BFA</a>, BFB))) announced today that Campbell P. Brown will step down as Chair of the Brown-Forman Board of Directors in July. Subject to his reelection at the annual meeting, he will continue to serve on the Board as a Director. Marshall B. Farrer, a fifth-generation descendent of the company's founder and a current Director of the Board, will assume the role of Chair of the Board, subject to his reelection to the Board.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20241125906365/en/">https://www.businesswire.com/news/home/20241125906365/en/</a>

Management

BF/A

Brown-Forman Announces Campbell P. Brown Will Step Down As Chair Of The Board Of Directors In July; Marshall B. Farrer, Will Assume The Role Of Chair Of The Board, Subject To His Reelection To The Board

APLMW

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

ASNS

Actelis Networks shares are trading higher after the company announced two expansion orders from the Washington DC Department of Transportation.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585aa876b5a482000151d0ee/kevin-grundy">Exane BNP Paribas analyst Kevin Grundy</a> initiated coverage on Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Neutral rating and announced a price target of $261. Constellation Brands shares closed at $239.66 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen analyst Joseph Thome initiated coverage on Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy rating. Viridian Therapeutics shares closed at $20.20 on Friday. <a href="https://www.benzinga.com/quote/VRDN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity analyst Edward Nash initiated coverage on Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy rating and announced a price target of $89. Apogee Therapeutics shares closed at $43.46 on Friday. <a href="https://www.benzinga.com/quote/APGE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Timothy Arcuri initiated coverage on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy rating and announced a price target of $160. ARM shares closed at $135.99 on Friday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announced a price target of $80. Sarepta Therapeutics shares closed at $114.23 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="621" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-1024x621.png" alt="" class="wp-image-663414" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Initiation

Pre-Market Outlook

APGE

SRPT

VRDN

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

AI, and specifically Generative AI with its ability for predictive analytics, is becoming a critical component of digital transformation and future business growth in almost all industries. Enterprise-grade data networks such as Verizon's will be instrumental in these processes, and Verizon continues to advance its network components to deliver on the promises of AI. In a recent trial in Boston, Verizon moved 1.6 Tb/s of data in its live fiber network on a single-carrier wavelength using <a href="https://www.globenewswire.com/Tracker?data=jEsaVB2cRTvK3bQqbyTHO0WZ7rGV6Qu4UgnYeJ6SxtN_4W-BZBlfjdBh34O8xVoBzGPGUPnsWwnc2VeDBgK_z1squs4lkiPD43cyhJp89LQHhxkBFwp9ztWYfoSj-5wBQ9yW8hUMf1OqKpN5YKbd3ikA1NCwioZaXHbWOK3yEDHTYxItAdo3NtR3o8Nt7Iy92cwJCAoob-856xQgiZwJgajud3S04kTfXQkZSmLilUzw715k6KbeGmzs4Niwfvn5BvPJK6e6SnUpZZVZzwrb1CyAM8twHYwLd50J5gRFFfViQ0DPUEFiI2pCngp3DkkEazk78a8DzBtkqjqNIgWEIebtCJjBdLpuE7OgwpZf46YBDAVuWNSbNmUNjjF66_fcqQUGq83OZsxHYLl7HltBVTcvceuz_mdGUXz-qnHxSScM1hdJoLlIqChXTjtZP6CgKqgoYpdbXAuJwZD1kGcBJcglFZ7w1i8RZteTvxF0iBiosrsQl8ru3ys_siIIHANXl-FGxMnX5RTQAdO-DYtOJA==">Ciena's</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) WaveLogic 6 Extreme (<a href="https://www.globenewswire.com/Tracker?data=KDfXHnLxFL6Ym-4uoiVOOK5wA1UpvHeruhAV72AO5TPZd3MSkVRXKc6u9vX1BYo-awwRn0n1j7u_Cg4iUJtKEoH_WTCjIrUMvZ7Yt2Yhj3VqQ05XqLRFywz0SfuWD7LcPwsTKpQAKs8ywklSgA5lM4nK-iGxrWkkaJkvmMHgfE-_gEzaXL64H21u2SzPjS1VGagX_QKjEu6rKviUFDuX6tk2iCJu2jR6sh3HQY5oSFai7hJQs2FMy9mnSZFlb484ngZAcA7bws7wXeBrV9SajMAcPCLzQt8M9yhN5YedR8I9Gk8pPUaw9ohwWR7UGbZpuThDbBIjzs3RFqgpyr-tv0_AIpYwhX8z0n-z6K1qDSDyWeUctrxZj5ShKn_xbSJSvaKt51MPdF2yQX3IC7Q2b4TVC8ANKNjwSXKxBzj0GLSUiBDr_FhQqtPjh9pXeQ-1A-_NE-lY0-3-QFlmne2ypuORdXuI7UE-pyIhb8duHONRkG8m1BWRGKJ0FRaxGTwosvWOotZZ0KqlHwweHsycvaNFhoVXK7sKkc1vpd607A8=">WL6e</a>) coherent optical solution. This next generation technology allows data traveling across Verizon's fiber network to travel farther and faster, leading to a better customer experience. In addition, the upgrade to this new equipment will result in higher reliability and significant energy savings in that portion of the fiber network.

CIEN

Verizon Advances Its Fiber Network For AI Workloads Using Ciena's WaveLogic 6, A Next Generation Technology That Allows Data Traveling Across Verizon's Fiber Network To Travel Farther And Faster

Mizuho analyst Ben Chaiken downgrades Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) from Outperform to Neutral and lowers the price target from $57 to $44.

Downgrades

Price Target

Mizuho Downgrades Red Rock Resorts to Neutral, Lowers Price Target to $44

With just six weeks left in 2024, Senate Majority Leader <a href="https://www.benzinga.com/topic/chuck-schumer">Chuck Schumer</a> (D-NY) faces mounting criticism for failing to deliver on his <a href="https://www.benzinga.com/markets/cannabis/24/03/37526202/chuck-schumer-senate-will-work-very-hard-to-pass-cannabis-banking-bill-before-upcoming-elections">long-standing promise</a> of achieving cannabis banking reform. Now, he&#8217;s mounting a Hail Mary effort to get it across the finish line before the term ends.
Senators on Capitol <a href="https://login.politicopro.com/?redirect=https://subscriber.politicopro.com/newsletter/2024/11/weed-banking-hopes-rise-again-00190071">told</a> Politico they &#8220;still have hopes the cannabis banking bill can get done in the lame duck, despite the odds.&#8221; 
What Happened: Schumer, who brought the <a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act" target="_blank" rel="noreferrer noopener">Secure and Fair Enforcement Regulation (SAFER) Banking Act</a> (SAFER) to a <a href="https://www.benzinga.com/markets/cannabis/23/09/34929327/breaking-senate-committee-approves-cannabis-banking-reform-in-historic-vote">committee hearing</a> in September 2023, had intended to advance the bill by attaching it to must-pass legislation before the midterms. However, despite his vocal support, he did not call the bill for a full Senate vote, citing insufficient Republican backing to overcome filibuster rules. This hesitation, coupled with Democrats&#8217; shifting priorities after this month's <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Republican electoral surge,</a> has all but killed hopes for cannabis banking reform during the lame-duck session.
And now, Senate Democrats are scrambling to address more immediate legislative tasks, including passing budget bills to avoid a looming <a href="https://www.benzinga.com/news/24/09/40931809/house-republicans-reject-their-own-funding-bill-as-government-shutdown-looms-mike-johnson-says-we-ha">Dec. 20 government shutdown</a> and finalizing judicial appointments before relinquishing control in January.
<h2 class="wp-block-heading">High Stakes As GOP Takes Congress</h2>
Senator <a href="https://www.benzinga.com/politics/24/11/41950681/trump-once-said-political-career-over-about-john-thune-now-senate-majority-leader-working-with-him-to-pass-gop-agenda">John Thune</a> of South Dakota who opposes marijuana legalization, is set to replace Sen. <a href="https://www.benzinga.com/topic/mitch-mcconnell" target="_blank" rel="noreferrer noopener">Mitch McConnell</a> as Senate majority leader. With Thune and conservative House Speaker Mike Johnson at the helm, the path to cannabis reform becomes even narrower. Johnson <a href="https://www.benzinga.com/markets/cannabis/23/10/35428675/buzz-kill-mike-johnsons-election-as-new-house-speaker-does-not-bode-well-for-cannabis-legalizati">has consistently voted against</a> most cannabis-related legislation, including banking reform.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41982165/new-gop-senate-leader-john-thune-opposes-marijuana-legalization-implications-for-banking-access-and-more">New GOP Senate Leader John Thune Opposes Marijuana Legalization: Implications For Banking Access And More</a>
Critics argue that Democrats, despite their rhetoric or best efforts, have fallen short of delivering substantive cannabis reform. Their missed opportunity leaves the industry bracing for continued financial instability.
Meanwhile, <a href="https://www.benzinga.com/24/11/42125955/cannabis-stocks-feel-the-burn-as-gaetz-bows-out-msos-in-focus">cannabis stocks tanked</a> last Thursday after pro-marijuana&nbsp;Matt Gaetz&nbsp;<a href="https://www.benzinga.com/24/11/42119848/matt-gaetz-withdraws-name-from-ag-nomination-calls-sex-trafficking-controversy-a-distraction" target="_blank" rel="noreferrer noopener">withdrew his nomination</a>&nbsp;for U.S. Attorney General and was replaced by the far less weed-friendly nominee Pam Bondi, a close associate of President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a>.
<h2 class="wp-block-heading">Looking Ahead</h2>
As the likelihood of meaningful cannabis reform fades under the outgoing Democratic administration, advocates are left with no choice but to turn to the incoming Republican leadership, hoping they embrace the stance candidate Donald Trump <a href="https://www.benzinga.com/markets/cannabis/24/08/40561136/trump-dislikes-having-people-in-jail-for-cannabis-will-he-legalize-if-elected-or-just-trying-to-">expressed back in August</a> at his Mar-a-Lago residence. 
&#8220;As we legalize it, I start to agree a lot more because it&#8217;s being legalized all over the country,&#8221; the president-elect said.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/42143770/trumps-pick-for-attorney-general-is-no-matt-gaetz-when-it-comes-to-cannabis-reform">Trump&#8217;s Pick for Attorney General Is No Matt Gaetz When It Comes To Cannabis Reform</a></li>
</ul>
Photo via Shutterstock

Government

Politics

Legal

GOP Takeover, Trump's Return Vs. Chuck Schumer's Last-Ditch Cannabis Banking Reform Push

CMAX

CareMax shares are trading lower after the company announced restructuring amidst its bankruptcy and delisting challenges.

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) shares are trading higher after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42159938/bath-body-works-reports-third-quarter-2024-results" rel="noreferrer noopener">third-quarter results and raised its 2024 outlook</a>.
BBWI&#8217;s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents.
Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
The gross margin was 43.5%, down 20 bps YoY, and the operating margin was 13.5% compared to 14.2% YoY.
Related: <a target="_blank" href="https://www.benzinga.com/24/11/42131172/bath-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" rel="noreferrer noopener">Bath &amp; Body Works Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
&#8220;Innovation across our core products, adjacencies, and collaborations is resonating with both new and existing customers supported by the investments we have made in marketing and technology. We are capitalizing on our agile business model and predominantly U.S.-based supply chain, and we believe we are well-positioned to navigate a volatile retail environment and shorter holiday calendar,&#8221; commented Gina Boswell, CEO of Bath &amp; Body Works.
Net cash used for operating activities year-to-date totaled $69 million, compared to cash provided of $28 million a year ago.
Bath &amp; Body Works exited the quarter with cash and equivalents of $191 million. The company&#8217;s inventories as of quarter end totaled $1.178 billion, with long-term debt of $3.88 billion.
Bath &amp; Body Works had recently declared a regular quarterly dividend of&nbsp;$0.20&nbsp;per share, payable on December 6, 2024, to shareholders of record at the close of <a target="_blank" href="https://www.benzinga.com//node/41842833" rel="noreferrer noopener">business on November 22, 2024.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/24/11/41855430/bath-body-works-stock-downgraded-due-to-this-risk-details" rel="noreferrer noopener">Bath &amp; Body Works Stock Downgraded Due To This Risk: Details</a>
Q4 Outlook: Bath &amp; Body Works projects net sales to decline of 6.5% to a decline of 4.5% year-over-year, reflecting a 500-basis-point headwind from a shifted fiscal calendar. Earnings per share are expected to be between $1.94 and $2.07, versus the $1.98 consensus.
2024 Outlook: The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% &#8211; 1.7% (prior view: decline of 4% &#8211; 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15&nbsp;&#8211; $3.28 <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(prior view $3.06&nbsp;&#8211; $3.26) versus the $3.18 consensus.</a>
Price Action: BBWI shares are trading higher by 19.2% at $36.61 premarket at the last check Monday.
Image via Unsplash

Equities

Guidance

Dividends

Movers

BBWI

Bath & Body Works Delivers Growth Amid Challenges, Beats Q3 Expectations And Lifts 2024 Projections

STKH

UMAMI Bioworks And Steakholder Foods Partner To Scale 3D-Printed Fish Fillets For Global Commercialization

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), adding that it's a &#8220;very <a href="https://www.benzinga.com/24/11/42084529/bhp-unveils-14-billion-capex-for-chilean-copper-operations">well-run&#8221; company.</a>
On Nov. 20, BHP announced plans to invest up to $14 billion to enhance its copper production in Chile, as revealed during a three-day site tour of its operations. This substantial capital expenditure aims to secure the long-term future of its assets in the region and support the growing global demand for copper.
Cramer said Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is a buy.
On Nov. 4, Diamondback Energy reported quarterly earnings of $3.38 per share, which missed the analyst consensus estimate of $3.99 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.44 billion.
When asked about AMC Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>), he said, &#8220;If it gets to six, I want you to sell it. Period. End of story.&#8221;
On Nov. 12, the company disclosed a debt retirement move in a SEC filing. The company said it entered into a series of privately negotiated agreements to retire $24.22 million in unsecured debt through 5.75% subordinated notes due 2025 <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41952040/amc-entertainment-shares-are-on-the-rise-today-whats-going-on">between Nov. 8 and Nov. 12</a>.
Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) is a &#8220;remarkable&#8221; company, Cramer said. &#8220;I need to see a pullback in Copart.&#8221;
On Nov. 21, Copart reported better-than-expected sales results for the first quarter.
Price Action:
<ul>
<li>BHP Group shares gained 0.7% to settle at $52.36 on Friday.</li>
<li>Diamondback Energy shares gained 1.4% to close at $185.29.</li>
<li>AMC Entertainment shares gained 1.3% to close at $4.55.</li>
<li>Copart shares jumped 10.2% to settle at $62.70 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Media

CPRT

FANG

Jim Cramer: Copart Is 'Remarkable,' BHP Is 'Well-Run,' Buy This Energy Stock

Vivani Medical GAAP EPS of -$0.10 beats by $0.02

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vivani Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/vani-stock-quote/">VANI</a>) just reported results for the second quarter of 2024.<ul><li>Vivani Medical reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -12 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vani-stock-earnings-vivani-medical-for-q2-of-2024/">VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024

Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Vivani Medical (VANI). Naz Rahman has given his Buy rating due to a comb...

Innovative Obesity Treatment Promises High Compliance: Buy Recommendation for Vivani Medical

Maxim Group analyst Naz Rahman reiterated a Buy rating on Vivani Medical (VANI – Research Report) yesterday and set a price target of $8.00. Naz Ra...

Buy Rating Affirmed for Vivani Medical on Strong Potential of NPM-115 Implant for Metabolic Disease Treatment

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical (VANI – Research Report) and keeping the price target at $8.00. Naz R...

Buy Rating on Vivani Medical: Advancing GLP-1 Therapies with Innovative Implantable Treatment

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

Vivani Medical GAAP EPS of -$0.11

Vivani Medical, Inc. ( ($VANI) ) has released its Q3 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investo...

Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials

Vivani Medical Gains 'Buy' Rating Due to Strategic Advancements and Financial Strength

ADBE

ALGM

ALLY

AVDX

BLNK

BYDDF

CAPR

CROX

CTRI

CYTK

DLTR

FIVE

HUBS

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRRK

TSLA

ULTA

USGO

VLKAF

VRSSF

ZYME

Press Releases

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Comments

Vivani Medical

Vendite allo scoperto

Vivani Medical (NASDAQ:VANI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO